Literature DB >> 11196185

Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis.

X H Yang1, T L Sladek, X Liu, B R Butler, C J Froelich, A D Thor.   

Abstract

MCF-7, a breast cancer-derived cell line, is deficient of caspase 3 and relatively insensitive to many chemotherapeutic agents. To study the association of caspase 3 deficiency and chemotherapeutic resistance, we reconstituted caspase 3 in MCF-7 cells and characterized their apoptotic response to doxorubicin and etoposide. Western blots demonstrated that caspase 3 was constitutively expressed in the reconstituted MCF-7 cells. Both morphological observation and survival assays showed that caspase 3 reconstitution significantly sensitized MCF-7 cells to both drugs. Remarkably increased activation of caspases 3, 6, and 7, cleavage of cellular death substrates, and DNA fragmentation were detected in the reconstituted MCF-7 cells after drug treatment. Together, these data demonstrated a specific role for caspase 3 in chemotherapy-induced apoptosis and in activation of caspases 6 and 7. Our results also suggest that caspase 3 deficiency may contribute to chemotherapeutic resistance in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196185

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  78 in total

1.  In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.

Authors:  Dexin Kong; Takao Yamori; Kanami Yamazaki; Shingo Dan
Journal:  Invest New Drugs       Date:  2014-08-26       Impact factor: 3.850

2.  GRIM-19 is essential for maintenance of mitochondrial membrane potential.

Authors:  Hao Lu; Xinmin Cao
Journal:  Mol Biol Cell       Date:  2008-02-20       Impact factor: 4.138

3.  A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin.

Authors:  Jan Lankelma; Rafael Fernández Luque; Henk Dekker; Jaap van den Berg; Bob Kooi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-18       Impact factor: 2.745

Review 4.  Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer.

Authors:  Huanjie Yang; Q Ping Dou
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

5.  Direct measurement of cathepsin B activity in the cytosol of apoptotic cells by an activity-based probe.

Authors:  Matthew R Pratt; Matthew D Sekedat; Kyle P Chiang; Tom W Muir
Journal:  Chem Biol       Date:  2009-09-25

6.  Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.

Authors:  Yan Cheng; Huaijun Li; Xingcong Ren; Tingkuang Niu; William N Hait; Jinming Yang
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

7.  Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.

Authors:  Jens C Hahne; Heike Schmidt; Susanne R Meyer; Jörg B Engel; Johannes Dietl; Arnd Honig
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-26       Impact factor: 4.553

8.  Different apoptotic effects of [Pt(O,O'-acac)(γ-acac)(DMS)] and cisplatin on normal and cancerous human epithelial breast cells in primary culture.

Authors:  Carla Vetrugno; Antonella Muscella; Francesco Paolo Fanizzi; Luca Giulio Cossa; Danilo Migoni; Sandra Angelica De Pascali; Santo Marsigliante
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

9.  Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells.

Authors:  Lilly Y W Bourguignon; Weiliang Xia; Gabriel Wong
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

10.  Several nuclear events during apoptosis depend on caspase-3 activation but do not constitute a common pathway.

Authors:  Lisa Trisciuoglio; Marco Emilio Bianchi
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.